Advanced search
Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 35, 2011 - Issue 5-6: The International Conference on Hemoglobin Disorders, Kuwait, February 5-7th, 2011 T.H.J. Huisman Memoriam
Submit an article Journal homepage
157
Views
13
CrossRef citations to date
0
Altmetric
PRESENTED AT THE INTERNATIONAL CONFERENCE ON HEMOGLOBIN DISORDERS, KUWAIT, February 5–7th, 2011

Use of Hormone Replacement Therapy for Correction of High Turnover Bone Disease in Hypogonadal β-Thalassemia Major Patients Presenting with Osteoporosis: Comparison with Idiopathic Premature Ovarian Failure

Ratna ChatterjeeInstitute For Women’s Health, University College London Hospitals, London, UK
,
Maurice KatzInstitute For Women’s Health, University College London Hospitals, London, UK
&
Rekha BajoriaInstitute For Women’s Health, University College London Hospitals, London, UKCorrespondence[email protected]
Pages 653-658 | Received 19 Jul 2011, Accepted 06 Sep 2011, Published online: 10 Nov 2011

REFERENCES

  • Bajoria R, Chatterjee R. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin. 2009;33(1):S136–S138.
  • Weatherall DJ. Pathophysiology of thalassaemia. Bailliére’s Clin Haematol. 1998;11(1):127–146.
  • Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β-thalassaemia disease. Clin Endocrinol (Oxf). 2003;58(3):273–279.
  • Kalef-Ezra J, Challa A, Chaliasos N, Bone minerals in β-thalassemia minor. Bone. 1995;16(6):651–655.
  • Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol (Oxf). 1995;42(3):279–287.
  • Wonke B, Jensen C, Hanslip JJ, Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab. 1998;11(suppl. 3):795–801.
  • Chatterton BE, Thomas CM, Schultz CG. Liver density measured by DEXA correlates with serum ferritin in patients with β-thalassemia major. J Clin Densitom. 2003;6(3):283–288.
  • Chan YL, Pang LM, Chik KW, Cheng JC, Li CK. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol. 2002;32(7):492–497.
  • Di Stefano M, Chiabotto P, Roggia C, Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab. 2004;22(1):53–57.
  • Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf). 2000;53(1):33–42.
  • Carmina E, Di Fede G, Napoli N, Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int. 2004;74(1):68–71.
  • Lasco A, Morabito N, Gaudio A, Osteoporosis and β-thalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest. 2002;25(4):338–344.
  • Bielinski BK, Darbyshire PJ, Mathers L, Impact of disordered puberty on bone density in β-thalassaemia major. Br J Haematol. 2003;120(2):353–358.
  • Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with β-thalassemia major. Osteoporos Int. 2001;12(7):570–575.
  • Morabito N, Lasco A, Gaudio A, Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int. 2002,13(8):644–649.
  • Voskaridou E, Terpos E, Spina G, Pamidronate is an effective treatment for osteoporosis in patients with β-thalassaemia. Br J Haematol. 2003,123(4):730–737.
  • Bajoria R, Sooranna SR, Chatterjee R. Type 1 collagen marker of bone turnover, IGF and leptin in dichorionic twins with discordant birth weight. J Clin Endocrinol Metab. 2006;91(11):4696–4701.
  • Harris ST, Eriksen EF, Davidson M, Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001;86(5):1890–1897.
  • Schnitzer T, Bone HG, Crepaldi G, Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000;85(2):720–726.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.